ProQinase, Mercachem Share Grant to Develop Epigenetics Platform | GenomeWeb

NEW YORK (GenomeWeb News) – ProQinase and Mercachem on Monday said they have been awarded €2.5 million ($3.2 million) to develop a new drug discovery platform targeting epigenetic enzyme families.

The three-year grant from the European Union's Eurostars program will be used to develop the platform, comprising novel biological and pharmacological assays, along with new chemical space libraries targeted against the most prominent epigenetic enzyme families, the partners said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.